Stephen Mok, Ph.D., Postdoctoral FellowThe University of Texas MD Anderson Cancer Center

The key to cancer research is about being persistent. Never lose hope and keep fighting to cure cancer.
Area of Research: All Cancers

Since ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) target different pathways, it’s not entirely surprising that these checkpoint inhibitors are associated with different types of patient responses. For example, anti-CTLA-4 treatment mediates extremely durable responses, while anti-PD-1 treatment can promote higher initial response rates. To figure out what is responsible for this, Dr. Mok is determining how each of these treatments affect memory T cell development, which allows the immune system to provide long-term, durable protection against cancer. Once it is known how each of these treatments influences potential long-term anti-tumor activity, then steps can be taken to amplify these effects and improve patient outcomes.

Projects and Grants

Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation

The University of Texas MD Anderson Cancer Center | All Cancers | 2016 | James P. Allison, Ph.D.

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.